Juno Launches With Competing Immunotherapy Programs
This article was originally published in Start Up
Executive Summary
The latest data from early cancer immunotherapy trials show patients in complete remission, reinforcing the field’s most-watched status. Juno Therapeutics is raising a war chest to capture programs from rival oncology research centers, but it doesn’t mean the competition has ended.
You may also be interested in...
Ocular Gene Therapy Sees The Light
Recent scientific advances and some initial biotech successes have spurred investors to look again at gene therapy, a space once given up for dead. Gene therapies seem particularly apt for ocular diseases, but the pathway to approval remains largely uncharted for young companies such as the four we profile in this issue: Avalanche Biotechnologies, Eyevensys, GenSight Biologics, and Hemera Biosciences.
A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy
Novartis’ deal with the University of Pennsylvania around cancer immunotherapies based on chimeric antigen receptor technologies developed in the lab of Penn’s Carl June comes at an opportune time. The Big Pharma is fighting to preserve its number two ranking in oncology and Penn’s high-profile, albeit much smaller, alliance with AstraZeneca in neurodegenerative disease is winding down.
With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers
Problems that led to the capsizing of Dendreon Corp.’s Provenge prostate cancer immunotherapy are particular to the company and product, some cancer vaccine makers are quick to say. Nevertheless, what the Street saw as a commercial disaster for the pioneering treatment bears lessons for those who follow in the budding space.